Mesoblast reports operational and financial highlights for quarter ended march 31, 2023

New york, may 25, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended march 31, 2023.
MESO Ratings Summary
MESO Quant Ranking